Literature DB >> 16136598

Mature T-cell leukemias.

Farhad Ravandi1, Hagop Kantarjian, Dan Jones, Claire Dearden, Michael Keating, Susan O'Brien.   

Abstract

Mature T-cell and NK-cell leukemias are a group of relatively uncommon neoplasms derived from mature or postthymic T-cells accounting for a relatively small percentage of lymphoid malignancies. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of these disorders from their B-cell counterparts. Similarly, identification of recurrent cytogenetic abnormalities, as well as plausible mechanisms through which these molecular events influence cellular signaling pathways, have created further insight into the pathogenesis of these disorders. Furthermore, the availability of new agents such as alemtuzumab has generated significant interest in devising specific therapeutic strategies for these malignancies. Herein, we review the clinical and pathological features of mature T-cell leukemias. (c) 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136598     DOI: 10.1002/cncr.21405

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro.

Authors:  Ke Lan; Masanao Murakami; Tathagata Choudhuri; Donald E Tsai; Stephen J Schuster; Mariusz A Wasik; Erle S Robertson
Journal:  J Clin Virol       Date:  2008-09-14       Impact factor: 3.168

3.  T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:  Geling Li; Emily Waite; Julie Wolfson
Journal:  Blood Adv       Date:  2017-12-18

4.  Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

Authors:  Farhad Ravandi; Ahmed Aribi; Susan O'Brien; Stefan Faderl; Dan Jones; Alessandra Ferrajoli; Xuelin Huang; Sergernne York; Sherry Pierce; William Wierda; Dimitrios Kontoyiannis; Srdan Verstovsek; Barbara Pro; Luis Fayad; Michael Keating; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

5.  Human T Lypmphotrophic Virus (HTLV1) Related Diseases.

Authors:  S Z Tabei
Journal:  Iran Red Crescent Med J       Date:  2011-06-01       Impact factor: 0.611

6.  Successful treatment of cancer-associated retinopathy with alemtuzumab.

Authors:  Ladan Espandar; Susan O'Brien; Charles Thirkill; Linda A Lubecki; Bita Esmaeli
Journal:  J Neurooncol       Date:  2007-01-25       Impact factor: 4.506

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.